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The post-entry events of HIV-1 infection occur within reverse transcription complexes derived from the
viral cores entering the target cell. HIV-1 cores contain host proteins incorporated from virus-producing
cells. In this report, we show that MCM5, a subunit of the hexameric minichromosome maintenance
(MCM) DNA helicase complex, associates with Gag polyprotein and is incorporated into HIV-1 virions.
The progeny virions depleted of MCM5 demonstrated reduced reverse transcription in newly infected
cells, but integration and subsequent replication steps were not affected. Interestingly, increased
packaging of MCM5 into the virions also led to reduced reverse transcription, but here viral replication
was impaired. Our data suggest that incorporation of physiological amounts of MCM5 promotes aberrant
reverse transcription, leading to partial incapacitation of cDNA, whereas increased MCM5 abundance
leads to reduced reverse transcription and infection. Therefore, MCM5 has the properties of an inhibitory
factor that interferes with production of an integration-competent cDNA product.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The pre-integration events of HIV infection (reverse transcrip-
tion, cytoplasmic trafﬁcking, and nuclear import of viral DNA) occur
within intracellular subviral particles called reverse transcription
complexes (RTCs), which become pre-integration complexes (PICs)
when cDNA processing is accomplished. These particles are derived
from the viral capsid cores entering the target cell. Certain host cell
proteins hijacked by virions from the virus-producing cells or re-
cruited from the newly infected cell have been shown to stimulate
[cyclophilin A (Briones et al., 2010; Luban, 2007; Luban et al., 1993;
Schaller et al., 2011), heat shock protein 70 (Gurer et al., 2002),
clathrin (Popov et al., 2011; Zhang et al., 2011), RNA helicase A
(Jeang and Yedavalli, 2006; Roy et al., 2006), INI1/hSNF5 and Sin3a-
HDAC1 complex (Sorin et al., 2009, 2006; Yung et al., 2004), im-
portins α1 (Gallay et al., 1997) and α3 (Ao et al., 2010), importin 7
(Fassati et al., 2003; Zaitseva et al., 2009), TNPO3/transportin-SR2
(Christ et al., 2008; Krishnan et al., 2010), lens epithelium-derivedInc. This is an open access article u
).growth factor (LEDGF) p75 (Ciufﬁ and Bushman, 2006; Llano et al.,
2006; Maertens et al., 2003), barrier-to-autointegration factor (BAF)
(Lin and Engelman, 2003), protein kinase A (PKA) (Giroud et al.,
2013), eukaryotic elongation factor 1 (eEF1) (Warren et al., 2012)] or
inhibit [apolipoprotein B mRNA editing enzyme catalytic (APOBEC)
3G (Bishop et al., 2008; Holmes et al., 2007b), APOBEC3F (Holmes
et al., 2007a), Sterile alpha motif domain- and HD domain-con-
taining protein (SAMHD) 1 (Hrecka et al., 2011; Laguette et al.,
2011), Moloney leukemia virus (MOV) 10 (Furtak et al., 2010), RNA-
associated early-stage anti-viral factor (REAF) (Marno et al., 2014)]
the early events of HIV replication. Our published results of the
proteomic analysis of HIV-1 cores (Santos et al., 2012) showed in-
corporation of multiple RNA- and DNA-binding proteins into the
cores of virions assembled in CD4þ T cell (Sup-T1) and macrophage
(PMA and vitamin D3 activated THP-1) lines. Some of the identiﬁed
cellular proteins incorporated preferentially from one of the pro-
ducer cell types, while the others, like the subunit 5 of the mini-
chromosome maintenance complex (MCM5), displayed incorpora-
tion into the cores of virions assembled in both T cells and macro-
phage lines, although the ratio of incorporation varied depending
on the cell type (Santos et al., 2012).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
S. Santos et al. / Virology 497 (2016) 11–2212The MCM2–7 heterohexamer is an essential replicative DNA
helicase that contains six related ATPase associated subunits
(MCM 2-7) required for both initiation and elongation of DNA
replication (Bailis et al., 2008; Bochman and Schwacha, 2009).
Within the MCM2–7 hexamer, the MCM4/6/7 components are the
“core” helicase, whereas the MCM3 and MCM5 subunits provide
the regulatory function (Chuang et al., 2012; Schwacha and Bell,
2001). The MCM2–7, a component of DNA pre-replicative complex,
is normally active in the nucleus during the late G1 and S phases of
the cell cycle and is essential for both the formation and main-
tenance of the replicative fork structure, as well as the reparation
of double-strand breaks (Bailis et al., 2008). Insufﬁcient amounts
of the MCM complex have been shown to impair the cell cycle and
lead to genomic instability (Bochman and Schwacha, 2009;
Chuang et al., 2012).
Previous studies have implicated the MCM helicase's involve-
ment in life cycles of Epstein-Barr Virus (EBV) (Frappier, 2012) and
Inﬂuenza Virus (Kawaguchi and Nagata, 2007). In the case of EBV,
EBNA1 (a viral protein that binds to the origin of replication)
speciﬁcally recruits the MCM helicase to assist in replication of
viral DNA during S phase, which is critical for the maintenance of
latent phase of infection. Inﬂuenza virus engages cellular MCM
helicase for the replication of viral RNA during the infection. Ka-
waguchi and Nagata (2007) showed that binding of the MCM
complex to the viral RNA-dependent RNA polymerase is required
for the formation of a productive complex. They also demonstrated
binding of the whole hexameric MCM complex to viral RNA and to
the PA subunit of the viral polymerase complex, probably through
the MCM2 subunit. They proposed that MCM acts as a “scaffold”
between the viral polymerase and the RNA, which is necessary for
elongation of RNA synthesis.
In the present study, we demonstrate a novel role for the
monomer MCM5 of the MCM complex in the HIV-1 life cycle. WeTable 1
MS/MS detection of MCM2–7 complex subunits in the cores of virions derived from dif
Cores of virions from MCM complex subunits
MCM2 MCM3 MCM4
Prot.
scorea
# of
pept.b
Prot.
score
# of
pept.
Prot.
score
Sup-T1, CEMNKR (CD4þ T
cells)
5.07 4 2.11 2 2.21
THP-1 (monocytes) þc 2.51
HEK293T
(epithelial) þ
a Log10 transorfmation of the protein identiﬁcation conﬁdence calculated from pep
100)].
b The number of proteotypic peptides detected by LC-MS/MS analysis
c Protein earlier detected only by Western blot (Santos et al., 2012).
Fig. 1. MCM5 is incorporated into HIV-1 virions via interaction with Gag polyprotein.
producing cells. HEK293T cells were transfected either with pCMV-MCM5 plasmid or pC
with pNL4-3; cells and culture supernatants were harvested 48 h after second transfecti
immune complexes were analyzed by SDS-PAGE and Western blot. (B) IP of HA-tagged M
described in A, equalized by p24 and lysed. The lysates were incubated or not with R
complexes were analyzed by SDS-PAGE and Western blot. (C) The HEK293T cells were tra
transfected with empty vector. The cells and culture supernatants were harvested, vira
subjected to SDS-PAGE and Western blot to test expression of MCM2, MCM3 and MCM5
and HIV-1 Gag (white). Cell nuclei were stained by DAPI (blue). Panel a shows a compo
arrows – cells not expressing Gag, and red arrow points to dividing cell. Single channel im
(E) Experiment was performed as in panel D, but staining was for MCM3 (green) and HIV-
negative cell – by yellow arrow. (F) Quantiﬁcation of images in panels D and E was perfor
were analyzed for MCM5 distribution, 41 Gag-positive and 26 Gag-negative cells were
ﬂuorescence intensity in the nucleus to that in cytoplasm. The difference in the ratio
signiﬁcant (po0.001 by Student's unpaired t-test). (G) Monocyte-derived macrophages w
as in panel D.show association of MCM5 subunit with HIV-1 Gag polyprotein
during the virion assembly and with viral cores in mature viral
particles. Our results suggest that MCM5 stimulates non-produc-
tive reverse transcription and, when overexpressed in HIV virions,
inhibits viral replication in the infected cells.2. Results
2.1. Detection of the monomers of MCM2-7 replication complex
within viral cores
Viral cores were isolated using the method of “spin-thru”
equilibrium density gradient sedimentation (Aiken, 2009; Ke-
walramani and Emerman, 1996; Kotov et al., 1999) from the sus-
pensions of HIV-1 NL4-3 virions harvested from T cells (Sup-T1),
macrophages (PMA-treated THP-1), and epithelial HEK293T cells
infected with the virus pseudotyped with amphotropic MLV en-
velope. LC-MS/MS analysis of in-solution trypsin digested core
samples revealed all components of cellular MCM2–7 complex in
cores of the virus produced from Sup-T1 and CEMNKR cells
(Table 1). This result is consistent with a report by Brégnard and
coauthors who have recently detected monomers of the MCM
complex via proteomic analysis of the whole virions of HIV-1 NL4-
3 produced by transfected HEK293T cells (Bregnard et al., 2013).
However, our analysis of the virus from HEK293T cells, as well as
from the monocytic cells THP-1, revealed only certain subunits,
and MCM5 was the only subunit detected in all preparations
(Table 1). To estimate incorporation of MCM5 into the virions, we
compared the ratio of MCM5- and p24-derived peptides in virions
produced from Sup-T1 cells to the ratio in virions from THP-1 cells.
This analysis demonstrated that MCM5/p24 ratio was 10-foldferent infected cell lines.
MCM5 MCM6 MCM7
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(A) Co-immunoprecipitation of MCM5 and Gag from cytoplasmic lysates of virus-
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of MCM5 ﬂuorescence between Gag-positive and Gag-negative cells was highly
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S. Santos et al. / Virology 497 (2016) 11–2214lower in Sup-T1-produced virions relative to the virions produced
by THP-1 cells, indicating that MCM5 incorporation varies de-
pendent on producer cell, and the number of MCM5 molecules per
virion is likely much smaller than the number of Gag molecules.
Based on these data, we suggest that MCM5 subunit of the re-
plicative helicase complex is incorporated in varying numbers into
HIV-1 virions from all types of virus producing cells.
2.2. Incorporation of MCM5 into HIV-1 virions depends on its in-
teraction with Gag polyprotein
Since all MCM subunits possess DNA-binding activity (Schwa-
cha and Bell, 2001), and at least some of them have been shown to
bind RNA and RNA polymerase of inﬂuenza A virus (Kawaguchi
and Nagata, 2007), we asked whether HIV-1 RNA or viral proteins
are involved in the MCM5 packaging into the virion. Anti-HA im-
munoprecipitation (IP) from cytoplasmic lysates of the virus-pro-
ducing HEK293T cells transfected with the vector expressing he-
magglutinin (HA)-tagged MCM5 revealed association of MCM5
subunit with unprocessed HIV-1 Gag polyprotein (Fig. 1A). Inter-
estingly, while many processed Gag molecules can be detected
within the cytoplasm of producer cells (CA p24 and MA p17 bands
in Fig. 1A, right panel), MCM5 co-immunoprecipitated mostly with
unprocessed (Pr55Gag) and C-terminally processed (Pr41Gag lacking
p6 and NC p7 domains) polyprotein-precursor, but not with pro-
cessed p17 or p24, suggesting localization of MCM at the sites of
virion assembly. However, analysis of the virion suspensions
equalized by p24 content, lysed with 0.5% Triton X-100 and im-
munoprecipitated with anti-HA antibody (to pull down MCM5)
identiﬁed stable association of MCM5 with CA p24 and especially
MA p17 Gag-derived viral proteins (Fig. 1B), suggesting that these
Gag molecules were responsible for interaction of the Gag pre-
cursor with MCM5. Treatment of immunocomplexes with RNase A
did not affect association of MCM5 with the Gag products, sug-
gesting that MCM5 binding with Gag is not mediated by the RNA
(Fig. 1B).
To test whether MCM5 is incorporated into the virions as a
component of MCM2–7 complex or as a separate protein via direct
interaction with Gag, we overexpressed MCM5 in the virus-pro-
ducing cells. Indeed, upon overexpression of MCM5 in HEK293T
virus-producing cells, more MCM5 was present in the HIV-1 vir-
ions (Fig. 1C, top panels). To exclude the possibility of non-speciﬁc
precipitation of MCM5 from overexpressing cells, we performed
virus-precipitating procedure on mock-infected 293T cells. No
MCM5 band was detected in the precipitate (not shown). The le-
vels of MCM2 and MCM3 appeared unchanged in the virions
collected from MCM5-transfected cells (Fig. 1C, right middle pa-
nel). This observation suggests that MCM5 might be incorporated
into the HIV-1 virus particles independent of other subunits of the
MCM complex, the notion consistent with results in Table 1.
To conﬁrm the association of MCM5 with HIV-1 Gag, HEK293T
cells were transfected with pNL4-3, immunostained with ﬂuor-
escently labeled antibodies, and analyzed by confocal microscopy.
Nuclei were counterstained with DAPI. As shown in Fig. 1D, in cells
not expressing HIV-1 Gag, MCM5 is localized primarily to the
nucleus (cells marked by yellow arrows in panel a). A cell in the
process of mitosis (marked by red arrow in panel a) shows MCM5
localization outside of the DAPI-stained area, consistent with
MCM5 release from the nucleus. In cells expressing HIV-1 Gag
(marked by white arrows in panel a), MCM5 is distributed
throughout the cell (see panels a and c) and is enriched in the area
of Gag localization. In contrast, a similar analysis of MCM3 (Fig. 1E)
demonstrated that localization of this protein did not change in
the presence of HIV-1 protein expression, and it remained in the
nuclei of cells regardless of Gag expression (cells expressing Gag
are marked by white arrows and Gag-negative cell - by yellowarrow in panel a). Quantiﬁcation of images using Volocity software
demonstrated redistribution of MCM5-speciﬁc staining from nu-
cleus to cytoplasm, signiﬁcantly decreasing the nucleus to cyto-
plasm ratio of ﬂuorescence intensity in HIV Gag-positive cells
(Fig. 1F). No such redistribution of ﬂuorescence was observed for
MCM3-speciﬁc staining. To demonstrate that the observed redis-
tribution of MCM5 was occurring in a natural HIV target cell type,
macrophage, we analyzed MCM5 in monocyte-derived macro-
phages infected with VSV-G-pseudotyped HIV-1 NL4-3. As shown
in panel G of Fig. 1, MCM5 localized exclusively to the nucleus in
the uninfected macrophages, but was distributed throughout the
cell in the Gag-positive macrophage. Taken together, these results
indicate that HIV-1 infection leads to exit of MCM5 from the nu-
cleus and its association with the Gag protein.
2.3. MCM5 deﬁcient virus displays decrease in cDNA accumulation
but not in nuclear import and integration in newly infected T cells
To test whether the lack of MCM DNA helicase in HIV-1 virions
affects the next round of infection, we used the virus derived from
cells treated either with MCM5 siRNA (MCM5 knockdown) or with
genistein (GST) and/or trichostatin A (TSA). GST and TSA are two
anticancer drugs that have been shown to affect MCM2 gene ex-
pression and reduce the functional activity of the whole MCM
complex (Majid et al., 2010). Of note, genistein has been reported
to inhibit HIV-1 replication in macrophages through both entry-
and post-entry effects due to its tyrosine kinase inhibitory activity
(Stantchev et al., 2007), while TSA is a known activator of HIV
transcription through its HDAC inhibitory activity (Quivy et al.,
2002). However, no information is available regarding the effect of
these drugs on viruses produced from drug-treated cells.
To determine the effect of these two drugs on MCM5 virion
incorporation, we treated infected SupT1 cells with the MCM he-
licase inhibitors and analyzed MCM5 incorporation after isolating
the newly produced virions. The GST concentration used in our
study (50 mM) was previously shown to be non-toxic to HEK293
cells (Kolokoltsov et al., 2012), and the TSA concentration (100 ng/
ml or 0.3 nM) was about 300-fold lower than the 100 nM con-
centration used in other HIV studies (e.g., (Quivy et al., 2002)).
Accordingly, no cytotoxic effect was observed and virus production
was not affected (not shown). As shown in Fig. 2A (two upper
panels), MCM5 protein levels remained unchanged or even in-
creased within cell lysates in the presence of either one or both
drugs. However, MCM5 was absent from the virions produced
from drug-treated cells (Fig. 2A – two lower panels). Taken to-
gether, these data suggest that the MCM5 monomer is in-
corporated into HIV-1 viral particles, and the functional activity of
MCM5, or possibly the whole MCM helicase, is important for
MCM5 incorporation into HIV-1 virions. Utilizing these manipu-
lated virus stocks, we then infected Jurkat cells and analyzed how
the absence of MCM5 within HIV-1 virions affects the early stages
of replication. Of note, the viruses were treated with DNAse I to
remove contaminating plasmid DNA.
Unchanged levels of the viral RNA measured within the target
cells harvested 2 h after incubation with the virus from drug-
treated cells indicated that the virion attachment and entry events
remained unaffected (Fig. 2B). This assay also indicated that the
levels of HIV-1 RNA incorporated into the virions were not affected
by MCM5 manipulation, an important possibility to exclude given
the MCM5 afﬁnity for RNA. However, we observed a two- to three-
fold decrease in accumulation of late cDNA copies (Fig. 2C). To
verify that this effect was due to reduced virion incorporation of
MCM5, and not to non-speciﬁc activity of the drugs, we utilized
siRNA to knockdown MCM5 within virus-producing HEK293T
cells. As shown in Fig. 2D, successful knockdown of MCM5 was
accomplished in 293T cells, and did translate to reduced MCM5
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Jurkat cells infected with HIV-1 produced from HEK293T cells treated with MCM5 siRNA or scrambled (control) siRNA. Nuclear import was assessed by quantitation of 2-LTR
circles at 24 post-inoculation. Results are shown as mean of three independent experiments7SEM. (H) Analysis of integration in Jurkat cells infected with HIV-1 produced
from HEK293T cells treated with MCM5 siRNA or scrambled (control) siRNA. Integration was quantiﬁed as described in F. Results are shown as mean of three independent
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primer set speciﬁc for strong-stop viral DNA. Results are shown as mean of three independent measurements7SEM.
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S. Santos et al. / Virology 497 (2016) 11–22 17incorporation in virions. As expected, a similar trend to that ob-
served with virus produced by cells treated with MCM-inhibiting
drugs was seenwhen the virus fromMCM5 silenced cells was used
for infection: accumulation of late cDNA copies was reduced
(Fig. 2E). Unexpectedly, the effects of MCM5 inactivation on re-
verse transcription did not translate into inhibition of post-reverse
transcription steps of HIV-1 replication: the number of integrated
proviral DNA copies in cells infected with the virus collected from
cells treated with GST or TSA was reduced only insigniﬁcantly
relative to control cells, and only virus from cells treated by a
combination of TSA and GST produced the number of integrated
DNA copies which was signiﬁcantly reduced, by 60% (Fig. 2F). For
cells infected with the virus produced by cells where MCM5 was
knocked down, we did not detect signiﬁcant differences in accu-
mulation of 2-LTR circles (Fig. 2G) or integrated provirus (Fig. 2H)
relative to infection with control virus, although there was a trend
to increased integration of MCM5-depleted virus. Given that the
decrease of MCM5 in virions was similar between different
treatments (Fig. 1A), the effect of the drug combination on virus
integration was likely due to an as yet uncharacterized activity of
the drugs unrelated to their effect on MCM5. Taken together, these
data suggest that virion-incorporated MCM5 stimulates reverse
transcription and accumulation of cDNA products in target cells,
but most of these products are unable to translocate into the nu-
cleus and integrate into the host chromatin.
2.4. Increased MCM5 incorporation into HIV-1 virions leads to re-
duced reverse transcription and viral integration in the infected cells
Since the above described experiments showed that depletion
of MCM5 in HIV-1 producing cells resulted in decreased1 – Untreated (control)
2 – MCM5 siRNA transfected
3 – GST treated
4 – CMV-MCM5 transfected 
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Fig. 4. Increased incorporation of MCM5, but not its deﬁciency in HIV-1 virions, leads
normalized NL4-3 virions from MCM5 siRNA-transfected, genistein-treated, or pCMV-MC
harvested at 48 h post-inoculation and subjected to RT-PCR analysis with the primers
ements7SEM. Asterisk indicates po0.05. (B) The TZM-bl cells were infected with the sa
luciferase activity. Results are shown as mean of three independent measurements7SEincorporation and reduced reverse transcription, we then in-
vestigated the effect of MCM5 overexpression on the next round of
infection. Fig. 3A demonstrates successful MCM5 overexpression
within HEK293T cells which did translate to increased levels of
MCM5 in HIV-1 virions. Analysis of viral particles collected from
5106 MCM5- or empty vector-transfected cells using HIV-IG
demonstrated that protein composition of the virions was very
similar, although less virus was produced by MCM5-transfected
cells (Fig. 3B). Our data indicate that increased incorporation of
MCM5 into the virions did not affect viral entry (Fig. 3C), but re-
sulted in approximately a 3-fold reduction of early reverse tran-
scription products (strong-stop cDNA, Fig. 3D) and a 5-fold de-
crease of the late reverse transcription products (positive strand
cDNA, Fig. 3E) in infected Jurkat cells. The same trend was ob-
served in viral DNA integration (Fig. 3F), where a 3-fold decrease of
integrated HIV-1 provirus was observed. To test whether the high
level of MCM5 in the virion affects initial stages of reverse tran-
scription, we analyzed dynamics of strong-stop cDNA accumula-
tion in isolated and permeabilized virions using endogenous re-
verse transcription (ERT) assay as described earlier (Warrilow
et al., 2008). We found that within the ﬁrst two hours, the cores of
virions from cells with overexpressed MCM5 accumulated 2-fold
fewer early reverse transcription products than the cores of virions
from control cells (Fig. 3G), consistent with the inhibitory effect of
virion-incorporated MCM5 on reverse transcription.
2.5. Virus with increased level of MCM5 incorporation displays re-
duced replication in the next round of infection
To test whether the differences in cDNA accumulation and in-
tegration induced by changes in abundance of MCM5 in the virions0
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1 – Untreated (control)
2 – MCM5 siRNA transfected
3 – GST treated
4 – CMV-MCM5 transfected 
Infection with HIV-1 from cells:
Infection of TZM-bl cells
to decreased HIV-1 viral replication in the infected cells. (A) The puriﬁed and p24
M5-transfected HEK293T cells were used for infection of Jurkat cells. The cells were
speciﬁc for HIV-1 Gag. Results are shown as mean of three independent measur-
me virus suspensions as in A, incubated for 72 h, lysed and subjected to analysis of
M; asterisk indicates po0.01.
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plication of the viruses using single-round infection. The HIV-1
unspliced RNA was quantiﬁed in the infected Jurkat cells and ac-
tivity of LTR-controlled luciferase was measured in TZM-bl re-
porter cells. Quantitative RT-PCR analysis of mRNA demonstrated
that reduction of MCM5 incorporation into the virions did not
signiﬁcantly change the level of HIV-1 RNA transcription (Fig. 4A).
In contrast, increased MCM5 incorporation into the virions re-
sulted in decreased transcription in infected Jurkat cells, evidenced
by a two-fold reduction in levels of HIV-1 RNA. A similar trend was
observed in infected TZM-bl cells, which carry luciferase gene
under control of HIV LTR. Small differences in the replication were
detected between viruses produced from control, MCM5 knocked
down cells or cells treated with MCM helicase inhibitor, but the
virus from cells overexpressing MCM5 demonstrated a 3–4-fold
lower level of luciferase activity (Fig. 4B). These data indicate that
increased abundance of MCM5 protein in HIV-1 virions leads to a
reduced efﬁciency of reverse transcription and integration, re-
sulting in the reduced level of total viral replication.3. Discussion
Results presented in this report indicate that the MCM5
monomer of the MCM2–7 DNA helicase is incorporated into HIV-1
virions from the virus-producing cells and regulates early events of
the next round of infection, speciﬁcally the step of reverse tran-
scription. Earlier studies suggested that MCM5 may act in-
dependently of other MCM subunits, for example, it directly binds
the transcription activator Stat1 in response to IFN-γ (DaFonseca
et al., 2001). Interestingly, both reduction and overabundance of
MCM5 in the virions inhibit reverse transcription. Given that re-
duction of MCM5 in the virions reduced the abundance of reverse
transcription products but did not reduce integration, it appears
likely that MCM5 promotes reverse transcription, but the excess of
reverse transcription products produced with participation of
MCM5 is composed of the molecules defective for integration. This
suggests that MCM5 impairs reverse transcription. Such inter-
pretation is consistent with the inhibitory effect on reverse tran-
scription of MCM5 overexpression, which may be explained by a
threshold hypothesis for the MCM5 effects: low (physiological)
MCM5 concentrations accelerate a portion of RT-driven reactions
at the expense of quality control, resulting in integration-defective
products, whereas levels of MCM5 above the threshold lead to
general impairment of reverse transcription and integration. This
effect of virion-incorporated MCM5 on reverse transcription sug-
gests interaction of this protein either with RT or with viral
genomic RNA (similar to inﬂuenza virus (Kawaguchi and Nagata,
2007)) and/or newly synthesized DNA product. Thus, similar to
MCM activity in inﬂuenza virus replication, the MCM5 monomer
in the HIV-1 RTC/PIC might assist in forming a scaffold between
nascent DNA and the RT molecule during initiation or elongation
of reverse transcription. Somehow, this scaffold, while promoting
reverse transcription, interferes with its completion, resulting in
accumulation of integration-defective cDNA copies. This effect on
completion of reverse transcription is further exacerbated when
MCM5 is overexpressed in the virions: increased number of MCM5
molecules may inhibit elongation of early reverse transcripts by
direct binding to viral genomic RNA and sterically hindering the RT
movement. A similar deamination independent mechanism was
earlier described for APOBEC3G (Bishop et al., 2008).
Our experiments do not fully exclude the possibility that ma-
nipulation of MCM5 levels in producer cells, rather than levels of
MCM5 incorporated into the virions, is responsible for the ob-
served effects on HIV infectivity. However, several lines of evi-
dence argue against this mechanism. First, the most likely target ofMCM5 is viral RNA, but we did not detect any effects of MCM5
manipulation in producer cells on the amount of viral RNA en-
tering the target cell (Fig. 2B). This result also suggests that
binding, fusion and entry proceeded normally. Second, although
MCM5 overexpression inhibited virus production, the ratio of HIV
proteins (RT, Env, and Gag) in virions was not changed when
MCM5 was overexpressed in producer cells (Fig. 3B). Third, the
behavior of the virus produced by cells with MCM5 knocked down
or inhibited (decrease in reverse transcription that does not
translate to decreased nuclear import or integration) is hard to
explain without invoking virion-associated protein. And fourth, it
is hard to imagine how both down- and upregulation of MCM5 in
producer cells can exert the same effect on HIV reverse tran-
scription in the target cells unless accepting the proposed model.
An important question for the future studies is the amount of
MCM5 molecules incorporated into HIV-1 virions. Our mass-spec
analysis did not establish absolute numbers, but demonstrated
that ratio of MCM5 to p24 is at least 10-fold lower in virions
produced from CD4þ T cells than from myeloid cells. It appears
that MCM5 incorporation varies dependent on producer cell, and
the number of MCM5 molecules per virion is likely much smaller
than the number of Gag molecules. It remains to be determined
whether MCM5 incorporation into HIV virions can be stimulated
by some physiological agent (e.g. cytokine), which would suggest a
novel anti-HIV therapeutic strategy.
The observed activities of MCM5 closely resemble those de-
scribed for another helicase, MOV10. Similar to MCM5, MOV10 is
incorporated into HIV-1 virions via interaction with the Gag
polyprotein, however, in contrast to MCM5 that co-precipitates
with CAp24 and MAp17, nucleocapsid region of Gag was required
for MOV10 incorporation (Abudu et al., 2012; Burdick et al., 2010;
Wang et al., 2010). MOV10 overexpression in virus producing cell
suppresses viral replication by inhibiting the early steps of reverse
transcription (Arjan-Odedra et al., 2012; Wang et al., 2010), again
closely resembling the effect of MCM5 overexpression. And
knockdown of endogenous MOV10 in virus producing cells did not
affect HIV-1 infectivity (Arjan-Odedra et al., 2012), similar to
MCM5 knockdown, although effects on reverse transcription have
not been investigated in that study. These similarities between
MOV10 and MCM5 are intriguing. Given that MOV10 is an RNA
helicase, whereas MCM5 is a DNA helicase, it seems reasonable
that the common target of their activity is reverse transcription.
Although endogenous levels of both these helicases do not alter
HIV-1 replication, the results of overexpression studies suggest an
intriguing possibility that helicases may function as inhibitors of
HIV reverse transcription. It remains to be tested whether the
concerted action of endogenous DNA and RNA helicases (MCM5
and MOV10, respectively) incorporated into the virions provides a
noticeable restrictive effect on HIV replication.4. Conclusions
Taken together, our data suggest that the incorporation of
physiological levels of MCM5 into HIV-1 virions facilitates viral
cDNA accumulation in newly infected cells, probably by modifying
nucleic acid conﬁguration during reverse transcription. However,
cDNA produced with participation of MCM5 is mostly defective for
subsequent integration, so depletion of MCM5 from the virions
does not lead to decreased integration or transcription. When
MCM5 in the virions is overabundant, it downregulates HIV-1
reverse transcription, integration, and replication. In this case, it is
likely due to further alteration of nucleic acid conﬁguration,
leading to a block in reverse transcription. Our data complements
a number of reports showing that the cellular proteins in-
corporated into the virions from producer cells can signiﬁcantly
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in Iordanskiy et al. (2013)). MCM5 has the properties of an in-
hibitory factor that limits HIV-1 replication by interfering with
production of an integration-competent cDNA product.5. Materials and methods
5.1. Cells and viruses
The acute monocytic leukemia cell line THP1 (from S. Tsuchiya),
T lymphoblastoma Sup-T1 cells (from James Hoxie) and TZM-bl
cells were provided by the NIH AIDS Research & Reference Reagent
Program. The human kidney ﬁbroblasts HEK293T and T lympho-
blasts Jurkat were purchased from ATCC (Manassas, VA). All cells
were maintained at 37 °C and 5% CO2 in 75 cm2 tissue culture
ﬂasks with RPMI-1640 culture media supplemented with 10% Fetal
Bovine Serum, penicillin/streptomycin (100 μg/ml), and
L-Glutamine.
The stocks of the HIV-1 virus were prepared by transfection of
HEK293T cells with HIV-1 NL4-3 provirus-encoding plasmid
(Westervelt et al., 1992) at a 1:4 ratio using Metafectene trans-
fection reagent (Biontex, Planegg, Germany). To generate the HIV-
1 pseudotyped with vesicular stomatitis virus glycoprotein (VSV-
G), the HEK293T cells were co-transfected with pNL4-3 and pCMV-
VSVG construct encoding VSV-G under control of CMV promoter.
After 4 h incubation with the transfection complex, the media was
changed and the cells were cultured in fresh media for 48 or 72 h
at 37 °C and 5% CO2. Then, the supernatants were harvested, ﬁl-
tered through a 0.45 mm ﬁlter and stored on wet ice at 4 °C for 1–4
days. Viruses were concentrated by centrifugation at 100,000 g
and 4 °C for 3 h through 2 ml cushions of 30% sucrose in PBS in a
Beckman SW-41 rotor. The pellets were re-suspended in 500 ml of
fresh culture media and used for infection. CD45-depletion was
performed using Human CD45 magnetic microbeads fromMiltenyi
Biotec (catalog no. 130-045-801) and performed according as
previously described (Chertova et al., 2006).
5.2. Infection
The viral suspensions were normalized according to their RT
activity, treated with 0.25 mg/ml DNase I RNase-free (Roche,
Mannheim, Germany) for 60 min in the presence of 5 mM MgCl2
at room temperature, mixed with Polybrene (Sigma) to a ﬁnal
concentration of 8 mg/ml and used for infection. Infection was
performed in 6-well plates (2.5106 cells per well). After 2 h in-
cubation at 37 °C and 5% CO2, the cells were washed from the
virus-containing media, re-suspended in RPMI-1640 (pre-warmed
to 37 °C) and incubated from 24 to 72 h.
5.3. Concentration of virus and “spin-thru” isolation of viral cores
The pellets of concentrated virus were re-suspended in 300 ml of
STE buffer and the viral cores were then isolated by “spin-thru”
puriﬁcation as described earlier (Aiken, 2009; Kewalramani and
Emerman, 1996; Kotov et al., 1999; Shah and Aiken, 2011). Brieﬂy,
3.8 ml of a 30–50% linear density gradient of sucrose in STE buffer
was overlaid with 1 ml of 15% sucrose containing 1% Triton X-100
and then covered with a 0.4 ml cushion of 7.5% sucrose in STE. The
HIV-1 positive and negative samples, concentrated through 30%
sucrose and resuspended in STE (0.3 ml) were carefully layered on
top of the 7.5% sucrose layer and centrifuged in a Type 100 Ti rotor
(Beckman Coulter) at 100,000 g at 4 °C for 16–18 h. The pellets
were re-suspended in 26 ml of STE buffer and placed into poly-
propylene non-siliconized Eppendorf microtubes; 4 ml aliquots were
set aside for the p24 CA ELISA assay. The CA p24Gag–normalizedsuspensions of HIV-1 cores and control suspensions were subjected
to SDS-PAGE protein separation for subsequent LC-MS/MS analysis,
Western blotting, or to in-solution protein digestion with trypsin for
the LC-MS/MS analysis of unseparated protein samples.
5.4. Gel separation of proteins, in-gel protein digestion and peptide
extraction
The volumes of viral core suspensions, each containing 400 ng
of p24 CA protein, and control suspensions taken in twofold excess
were mixed with equal volumes of Laemmli Sample Buffer
(BioRad, Hercules, CA) containing 5% βmercaptoethanol, heated in
boiling water for 2 min and applied for SDS-PAGE protein se-
paration. Separation of proteins was performed in 12.5% Tris–HCl
Criterion Precast Gel (BioRad) at 100 V and 4 °C for 2–2.5 h. The gel
was stained in 0.1% (wt/v) Coomassie (BioRad) solution (40% me-
thanol (v/v), 10% acetic acid (v/v) in water with 1 g/L of Brilliant
Blue R-250) for 1 h at room temperature. After 7–8 washes in de-
staining solution (contains the same components, as staining so-
lution, except Brilliant Blue R-250) the gel was placed into water,
and each lane was sectioned into 10 contiguous pieces, which
were subjected to proteolysis according to the modiﬁed previously
published protocol (Formolo et al., 2011). Brieﬂy, acetonitrile (ACN)
dehydrated gel pieces were rehydrated in 10 mM DTT and in-
cubated at 60 °C for 1 h. After cooling at room temperature, the gel
slices were incubated with 50 mM iodacetamide for 1 h at room
temperature in the dark for alkylation of proteins. After the second
dehydration, a 15 ml dose of Trypsin Gold (Promega, Madison, WI)
solution (20 mg/ml) in 40 mM NH4HCO3/10% ACN was added to
each of the gel pieces. After 1 h saturation at 4 °C, the pieces were
incubated at 37 °C overnight. The resulted peptides were extracted
three times: (1) with 25 mM of NH4HCO3:ACN (1:1); (2) 5% formic
acid (FA); (3) 5% FA:ACN (1:1). After pooling all the extracts to-
gether, samples were puriﬁed through ZipTip pipette tips C18
(Millipore), eluted with 30 ml of 0.1% triﬂuoroacetic acid (TFA) in
80% ACN and subjected to HPLC separation and MS/MS analysis.
5.5. In-solution protein digestion
The suspensions of HIV-1 cores after “spin-thru” centrifugation
were treated with 10 mM DTT (60 °C for 1 h) and 150 mM ioda-
cetamide (1 h at room temperature in the dark) in 20 l of STE
buffer. The protein samples were then mixed with 100 ml of
200 mM ammonium bicarbonate and treated with 200 ng of
Trypsin Gold (Promega) at 37 °C overnight. The resulted peptides
were dried in SpeedVac, resuspended in water, puriﬁed through
ZipTip pipette tips C18 as described above and then subjected to
HPLC separation and MS/MS analysis.
5.6. HPLC-MS/MS of tryptic digests and database search
The peptides in each sample were separated by micro-capillary
reversed-phase liquid chromatography (HPLC), coupled online to
an ion trap mass spectrometer Thermo LTQ Orbitrap XL. The mass
spectrometer was operated in a data-dependent MS/MS mode
using normalized collision-induced dissociation (CID) energy of
35%. The CID spectra were compared against those of the EMBL
non-redundant protein database. Only peptides having cross-cor-
relation (Xcorr) cutoffs of 2.6 for [Mþ2H]2þ , 3.0 for [Mþ3H]3þ and
higher charge state were considered. These SEQUEST criteria
thresholds resulted in a 1–2% of False Discovery Rate. The pro-
teome analysis of the spectra was made by Proteome Discoverer
1.2 software (Thermo Fisher Scientiﬁc). The protein proﬁles of the
samples of viral cores were compared with identically prepared
samples from non-infected cells. The sub-cellular localization and
function of each ﬁltered protein was determined using gene
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protein's Swiss-Prot accession number to the GO localization in-
formation available on the NCBI protein database (http://www.
ncbi.nlm.nih.gov/sites/entrez? db¼Protein) and The Human Pro-
tein Atlas database (www.proteinatlas.org). The involvement of
the proteins in known cellular pathways associated with major
biological processes such as cell cycle, intracytoplasmic transport,
cytoplasm organization, nuclear transport, chromatin structure
maintenance/regulation, RNA splicing and reorganization, tran-
scription, apoptosis, proteasomal degradation, etc. were assessed
using NCBI RefSeq database (www.ncbi.nlm.nih.gov/RefSeq/) and
DAVID Bioinformatics Resources 6.7 (NIAID NIH) (http://david.
abcc.ncifcrf.gov).
5.7. Western blot analysis
The aliquots of the lysates of HIV-1 infected cells and the virus
samples were subjected to SDS-PAGE, transferred to a PVDF
membrane and then blotted using the following antibodies: anti-
HIV-1 p24 (24-3) mouse monoclonal antibody, human HIV im-
munoglobulin (HIV-IgG), and for integrase - a combination of
rabbit antiserum for integrase (aa 1–16, 23–34 or 276–288) from
NIH AIDS Research & Reference Reagent Program; monoclonal
rabbit GAPDH (G9545) from Sigma-Aldrich, anti-MCM5 (G-1)
mouse monoclonal and anti-MCM3 (G-19) goat polyclonal anti-
bodies from SantaCruz Biotechnology (Santa Cruz, CA). Speciﬁc
bands were visualized by ECL (Thermo Scientiﬁc, Rockford, IL).
Quantiﬁcation of the Western blotting results was performed
using ImageJ software.
5.8. Plasmid preparation
The MCM5 plasmid was ordered from the Thermo Scientiﬁc's
Mammalian Gene Collection (clone ID: 2900229). Hemagglutinin
(HA)-tagged MCM5 was created using HindIII and BamHI and the
following primers: 5′-CTCCCCTGGTTTGTGAAGCTTGGAAAA-3′ and
5′-CAGTGAGGCGGCGCGGATCCCTTGAGGCGGTAGAG-3′. The am-
pliﬁed MCM5 gene was then inserted into a phCMV3 HA TAG
vector using the Fast-Link Ligation System/Protocol.
5.9. Transfections
Plasmids were transfected into 293T cells to overexpress MCM5
with/without the HA tag using Metafectene according to the
manufacturer's recommendations. To knockdown MCM5, siRNA
was utilized and the SMARTpool of siRNA for MCM5 was ordered
from Dharmacon (Thermo Fisher Scientiﬁc, Waltham, MA). To
transfect siRNA into the cells, Dharmacon's specialized lipid re-
agent (Dharmafect 1) was used according to manufacturer speci-
ﬁcation. For siRNA controls, scrambled siRNA ordered from Dhar-
macon was used as control. We have observed that in the context
of these experiments no difference was detected between cells
transfected with scrambled siRNA and mock-transfected cells.
5.10. RNA puriﬁcation and RT reaction
RNA was puriﬁed from samples using TRI Reagent-LS (MRC,
Cincinnati, OH) according to the manufacturer’s protocol. A total of
0.5 μg of RNA from the RNA fraction was treated with 0.25 mg/ml
DNase I RNase-free (Roche, Mannheim, Germany) for 60 min in
the presence of 5 mM MgCl2, followed by the heat inactivation at
65 °C for 15 min. A 250 ng aliquot of total RNA was used to gen-
erate cDNA with the GoScript Reverse Transcription System (Pro-
mega, Madison, WI) using oligo-dT reverse primers.5.11. DNA isolation and quantitative real-time PCR
Lysates of HIV-1 infected cells were normalized to the total
protein count using DC Protein Assay (BioRad) following manufac-
turer's protocol. The total DNA was isolated using Wizard Genomic
DNA Puriﬁcation Kit (Promega, Madison, WI) following manufac-
turer's recommendations. After isolation, the cellular DNA samples
were analyzed by quantitative TaqMan real-time PCR to quantify
chromosomal DNA. Set of primers speciﬁc for the β-globin gene has
been used: forward primer BGF1 (5′-CAACCTCAAACAGACACCATGG-
3′), reverse primer BGR1 (5′-TCCACGTTCACCTTGCCC-3′), and probe
BGX1 (5′-FAM-CTCCTGAGGAGAAGTCTGCCGTTACTGCC-TAMRA-3′).
PCR reactions were performed with PerfeCTa qPCR FastMix, UNG
(Quanta Biosciences, Gaithersburg, MD) using 300 nM of each pri-
mer and 200 nM of probe according to the manufacturer protocol.
To quantitate viral cDNA, total DNA samples were analyzed by real-
time PCR using two sets of primers. The ﬁrst set detects the nega-
tive-strand “strong-stop” DNA (the early reverse transcription pro-
duct) and consists of forward primer M667 (5′-GGCTAACTAGG-
GAACCCACTG-3′), reverse primer AA55 (5′-CTGCTAGAGATTTTCCA-
CACTGAC-3′), and probe Er-LTR (5′-FAM-GTCACACAACA-
GACGGGCACACACTA-TAMRA-3′) speciﬁc for the R-U5 region of the
HIV-1 LTR. The second set recognizes the positive-strand DNA (late
reverse transcription product) and consists of primers: FOR-LATE
(5′-TGTGTGCCCGTCTGTTGTGT-3′), REV-LATE (5′-GAGTCCTGCGTC-
GAGAGATC-3′), and probe Lt-LTR-Prb (5′-FAM-CAGTGGCGCCCGAA-
CAGGGA-TAMRA-3′) speciﬁc for the U5-Ψ LTR region (Butler et al.,
2001). Quantitative analysis of 2-LTR circles was performed ac-
cording to published protocol (Butler et al., 2001) using the forward
primer MH535 (5′-AACTAGGGAACCCACTGCTTAAG-3′), reverse pri-
mer MH536 (5′-TCCACAGATCAAGGATATCTTGTC-3′), and probe
MH603 (5′-FAM-ACACTACTTGAAGCACTCAAGGCAAGCTTT-TAMRA-
3′). Viral 2-LTR circles were detected from 500 ng total cellular DNA.
Two-step nested PCR assays were used for quantitative HIV-1 DNA
integration analysis. The ﬁrst round PCR was performed in a 25 ml
reaction mix as described in (Butler et al., 2001; O’Doherty et al.,
2002). Brieﬂy, 100 nM of the genomic Alu forward primer, Alu-F (5′-
GCCTCAATAAAGCTTGCCTTGA-3′), 600 nM of HIV-1 gag reverse
primer, Gag-R (5′-GCTCTCGCACCCATCTCTCTCC-3′), and 100 ng of
cellular genomic DNA were mixed with 1.5 mM MgCl2, 0.25 mM
dNTPs, 0.05 U of Platinum Taq DNA polymerase (Invitrogen) and Taq
polymerase reaction buffer (Invitrogen). The conditions were 2 min
hot start at 940 C, then 30 s at 93 ° C, 1 min at 50 °C, and 2 min at
70 °C for 20 cycles. The second round was performed with 5 ml of
the material from the ﬁrst round in 20 ml of reaction mix. The pri-
mer set and reaction conditions were the same as for quantitative
detection of the positive-strand HIV-1 DNA, as described above. The
2 ml aliquots of RT reaction mixtures of the RNA samples (see above)
were diluted 10-fold and 100-fold and subjected to quantitative
real-time PCR analysis with the set of primers speciﬁc for HIV-1 gag.
The primers Gag1483-F (5′-AAGGGGAAGTGACATAGCAG-3′) and
Gag1625-R (5′-GCTGGTAGGGCTATACATTCTTAC-3′) were used for
PCR reaction with iTaq Universal SYBR Green Supermix (BioRad,)
according to the manufacturer protocol. Serial dilutions of DNA
from 8E5 cells (CEM cell line containing a single copy of HIV-1 LAV
provirus per cell) were used as the quantitative standards. Real-
time PCR reactions were carried out at least in triplicate using the
PTC-200 Peltier Thermal Cycler with Chromo4 Continuous Fluor-
escence Detector (both from MJ Research) and Opticon Monitor
2.03 software.
5.12. Endogenous reverse transcription
The assay was performed as described (Zhang et al., 1996) with
some modiﬁcations. Prepared virus was resuspended in PBS to a p24
CA concentration of 1.5 ng/ml (200 ml of virus suspension required).
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PBS, 50 ml of 50 mMMgCl2, 50 ml of 300 m/ml melittin [Sigma], 100 ml
of 10 mM dNTP Mix [Promega]), and separately with 2 ERT control
buffer (275 ml PBS, 50 ml of 50 mM MgCl2, 50 ml of 300 m/ml melittin
[Sigma], 125 ml of 20 mM nevirapine [NIH AIDS Reagent Program]).
The mixtures were then aliquoted and frozen. After all time points
were collected, DNA was isolated and quantiﬁed using above de-
scribed PCR methods for early cDNA accumulation.
5.13. Luciferase assay
TZM-bl cells were plated in 96-well plates a day prior to in-
fection. The following day, cells were infected with normalized
virus and left for approximately 4–5 h, after which cells were
washed with PBS three times and cultured in DMEM. At 48 h post-
infection, cells were lysed using the cell culture lysis reagent
provided by the Promega Luciferase kit, from which point the
manufacturer's protocol was followed.
5.14. Co-immunoprecipitation
Anti-HA Beads were ordered from Sigma Aldrich and were
utilized to immunoprecipitate HA-tagged proteins (MCM5). The
immunoprecipitation was done on either cell lysates or the virions
lysed in 0.5% Triton X-100 according to the protocol provided by
the manufacturer at 4 °C overnight. To check if binding was RNA-
related, the lysates were treated with RNase A at a ﬁnal con-
centration of 10 mg/ml (Sigma Aldrich) during the overnight
incubation.
5.15. Drug treatment of cells to inhibit the MCM helicase
Genistein (GST) and Trichostatin A (TSA) were both ordered
from Sigma Aldrich. Approximately 24 h prior to transfection with
NL4-3 plasmid to produce virions, HEK293T cells were freshly
plated and incubated with 50 mM GST and/or 100 ng/ml TSA. The
next day, NL4-3 viral plasmid was transfected into the same cells
to produce virus as described above.
5.16. Confocal imaging
Cell culture preparation, transfections, immunostaining, and
imaging were performed as described previously with some mod-
iﬁcations (Jennelle et al., 2014). Brieﬂy, HEK293T cells were grown
on coverslips, transfected with pNL4-3 and/or pCMV-MCM5 as
described above. Two days post-transfection, cells were ﬁxed with
3.5% paraformaldehyde (room temperature, 7 min), permeabilized
with 0.1% Triton X-100 (room temperature, 5 min), blocked with 1%
BSA in PBS (þ4 °C, overnight), immunostained (see below), and
mounted on microscopic glass slides using Fluoromount G. HIV-1
Gag was visualized using mouse monoclonal anti-HIV Gag antibody
(NIH AIDS Research Program) followed by DyLight 550 goat anti-
mouse IgG antibody (MyBiosource), and for staining of endogenous
MCM5 or MCM3, rabbit monoclonal anti-MCM5 or anti-MCM3
antibody (Abcam) was followed by goat anti-rabbit IgG antibody
(Invitrogen) conjugated to Alexa Fluors 647 or GFP, respectively.
Images were captured with Cell Observer Spinning Disk ﬂuorescent
microscope (Carl Zeiss) using a Glycerine immersion lens 150 /
1.35 or with Carl Zeiss LSM 710 confocal microscope using a Plan
Apochromat 63 /1.4 Oil DIC lens (Zeiss). Further image processing
was performed using Volocity and ImageJ software.
5.17. Statistical analysis
All results are presented for one representative experiment out
of at least two performed. Quantitative data were analyzed bytwo-way ANOVA (OriginPro v. 8.0) and Student's t-test (Microsoft
Excel). Standard deviation was calculated in all quantitative ex-
periments for at least three independent preparations. The dif-
ference was considered to be statistically signiﬁcant when
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